Table 3.
Outcome measures for patients receiving rituximab prophylaxis
| Measure | Total (N = 76) | Standard dose (n = 24) | Reduced dose (n = 19) | Intermediate dose (n = 17) | Other doses (n = 16) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/N | % | Months (range) | n/N | % | Months (range) | n/N | % | Months (range) | n/N | % | Months (range) | n/N | % | Months (range) | |
| No. of patients in CR (ADAMTS13 ≥60%) | 60/76 | 78.9 | 18/24 | 75 | 16/19 | 84.2 | 12/17 | 70.6 | 14/16 | 87.5 | |||||
| No. of patients in PR (ADAMTS13 30%-59%) | 10/76 | 13.2 | 3/24 | 12.5 | 2/19 | 10.5 | 4/17 | 23.5 | 1/16 | 6.25 | |||||
| No. of patients achieving at least a PR (ADAMTS13 ≥30%) | 70/76 | 92.1 | 21/24 | 87.5 | 18/19 | 94.7 | 16/17 | 94.1 | 15/16 | 93.4 | |||||
| Time to ADAMTS13 recovery | 1 (<1-5) | 1 (<1-5) | 2 (<1-4) | 1 (<1-3) | 2 (<1-4) | ||||||||||
| Median overall follow-up | 15 (1-141) | 17.5 (1-141) | 25 (9-43) | 10 (3-20) | 21 (3-112) | ||||||||||
| No. of patients requiring re-treatment | 38/76 | 50 | 12/24 * | 50 | 14/19 * | 73.7 | 3/17 | 17.6 | 10/16 | 62.5 | |||||
| Re-treatment episodes per year | 0.25 | 0.17† | 0.38† | 0.20 | 0.29 | ||||||||||
n/N, number/total.
*
There was no significant difference in proportion of patients requiring re-treatment in standard- vs reduced-dose groups (P = .13).
†
The rate of re-treatment was significantly lower in the standard- vs reduced-dose group (0.17 vs 0.38 episodes per year, respectively; P = .039).